Baseline patient characteristics (N = 29)
| Variable . | Value . |
|---|---|
| Total | 29 (100) |
| Median age (range), y | 57 (22-76) |
| Histology | |
| DLBCL | 12 (41) |
| PMBCL | 5 (17) |
| TCR-BCL | 2 (7) |
| Transformed indolent NHL | 6 (21) |
| Relapsed after first-line therapy | 21 (72) |
| Relapse <12 mo (n = 21) | 11 (52) |
| Primary refractory to first-line therapy | 8 (28) |
| Baseline at relapse | |
| Median IPI (range) | 2 (1-3) |
| Median saaIPI (range) | 1 (0-2) |
| Median previous lines of therapy | 2 |
| Salvage regimens before ASCT | |
| R-ICE | 24 (84) |
| R-GDP | 2 (7) |
| DA-EPOCH-R | 1 (3) |
| R-HIDAC | 1 (3) |
| R-DHAP | 1 (3) |
| Conditioning regimen | |
| BEAM | 27 (93) |
| TBC | 2 (7) |
| Median time (range) from ASCT to first dose of pembrolizumab, d | 34 (28-57) |
| Disease status before ASCT | |
| Partial remission | 11 (38) |
| CR | 18 (62) |
| Disease status at study entry (post-ASCT) | |
| Partial remission | 4 (14) |
| CR | 25 (86) |
| Variable . | Value . |
|---|---|
| Total | 29 (100) |
| Median age (range), y | 57 (22-76) |
| Histology | |
| DLBCL | 12 (41) |
| PMBCL | 5 (17) |
| TCR-BCL | 2 (7) |
| Transformed indolent NHL | 6 (21) |
| Relapsed after first-line therapy | 21 (72) |
| Relapse <12 mo (n = 21) | 11 (52) |
| Primary refractory to first-line therapy | 8 (28) |
| Baseline at relapse | |
| Median IPI (range) | 2 (1-3) |
| Median saaIPI (range) | 1 (0-2) |
| Median previous lines of therapy | 2 |
| Salvage regimens before ASCT | |
| R-ICE | 24 (84) |
| R-GDP | 2 (7) |
| DA-EPOCH-R | 1 (3) |
| R-HIDAC | 1 (3) |
| R-DHAP | 1 (3) |
| Conditioning regimen | |
| BEAM | 27 (93) |
| TBC | 2 (7) |
| Median time (range) from ASCT to first dose of pembrolizumab, d | 34 (28-57) |
| Disease status before ASCT | |
| Partial remission | 11 (38) |
| CR | 18 (62) |
| Disease status at study entry (post-ASCT) | |
| Partial remission | 4 (14) |
| CR | 25 (86) |
Values are n (%) unless otherwise noted.
BEAM, carmustine, etoposide, cytarabine, melphalan; DA-EPOCH, dose-adjusted, etoposide, prednisone, vincristine, cyclophosphamide, hydroxydaunorubicin; DHAP, dexamethasone, high-dose cytarabine, cisplatin; GDP, gemcitabine, dexamethasone, cisplatin; HIDAC, high-dose cytarabine; ICE, ifosfamide, carboplatin, etoposide; IPI, International Prognostic Index; NHL, non-Hodgkin lymphoma; R, rituximab; saaIPI, second-line age-adjusted International Prognostic Index; TBC, thiotepa, busulfan, cyclophosphamide; TCR-BCL, T-cell–rich B-cell lymphoma.